$CYBN News

Last published 10mo ago

10mo agoCYBNCybin Initiates At-The-Market Equity Program of up to US$100 MillionBusiness WireCybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation
10mo agoCYBNCybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced
12mo agoCYBNCybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business HighlightsBusiness Wire- Closed registered direct offering for aggregate gross proceeds of US$175 million (the "Registered Direct Offering") led by a syndicate of prominent biopharmaceutical institutional investors - - On track to report
12mo agoCYBNCybin to Participate in the Jefferies Global Healthcare Conference in LondonBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms
1y agoCYBNCybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025Business Wire- Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry
1y agoCYBNCybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms
1y agoCYBNCybin to Participate at the 2025 Milken Institute Future of Health SummitBusiness Wire- Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company
1y agoCYBNCybin Announces Closing of $175 Million Registered Direct OfferingBusiness WireCybin Inc. (Cboe CA: CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery
1y agoCYBNCybin Announces $175 Million Registered Direct OfferingBusiness Wire- Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors - - Use of Proceeds Includes Repayment of High Trail Convertible Note in Full - Cybin Inc. (Cboe CA: CYBN) (NYSE:CYBN)
1y agoCYBNCybin Highlights Neuropsychiatry Platform and Upcoming Clinical MilestonesBusiness Wire- Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company's deuterated dimethyltryptamine ("DMT") program for the treatment of Generalized Anxiety Disorder ("GAD"). Topline data
1y agoCYBNCybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety DisorderBusiness Wire- The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose - - Reaffirms top-line data guidance for Q1 2026 - Cybin Inc. (NYSE:CYBN) (Cboe
1y agoCYBNCybin to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin to Participate in the Cantor Global Healthcare Conference 2025Business WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Announces Senior Leadership ChangesBusiness WireDoug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplement
1y agoCYBNCybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire- EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia - - Recently cleared to initiate
1y agoCYBNCybin Announces Results of Annual Meeting of ShareholdersBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial ResultsBusiness WireCybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones - Received European and United Kingdom Medical and Healthcare
1y agoCYBNCybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire- EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia - - European CTA
1y agoCYBNCybin to Participate in the Canaccord Genuity 45th Annual Growth ConferenceBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire- EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will commence imminently - -
1y agoCYBNREPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible DebenturesBusiness Wire- Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004
1y agoATAI CMPS CYBN MNMD+1Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032GlobeNewswirePALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years
1y agoCYBNCybin Reports Fiscal Year 2025 Financial Results and Recent Business HighlightsBusiness Wire- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study
1y agoCYBNCybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible DebenturesBusiness Wire- Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004
1y agoCYBNCybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic TherapeuticsBusiness Wire- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH™,
1y agoCYBNCybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives ConferenceBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin to Participate in the 2025 Psychedelic Science ConferenceBusiness Wire- Cybin CEO Doug Drysdale to participate in a panel discussion titled "The Home Stretch: Pivotal Trials and Preparing for Launch" on June 19, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a
1y agoCYBNCybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety DisorderBusiness Wire- Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - -
1y agoCYBNCybin to Participate in Water Tower Research Fireside Chat on May 29, 2025Business WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic TherapeuticsBusiness Wire- U.S. Food and Drug Administration ("FDA") Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health - - Calls for FDA to be open to innovative
1y agoCYBNCybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire- Thermo Fisher Scientific, the world leader in serving science, is providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 - - Production of both drug substance
1y agoCYBNCybin to Participate in the Alliance Global Partners Healthcare Company ShowcaseBusiness WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive DisorderBusiness Wire- Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 - - Cybin's growing intellectual property portfolio comprises more than 80
1y agoCYBNCybin to Participate at the 28th Annual Milken Institute Global ConferenceBusiness Wire- Doug Drysdale, CEO, to appear on panel entitled "The Global Landscape and Opportunities for Medical Breakthroughs," on May 5, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage
1y agoCYBNCybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003Business Wire- Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two
1y agoCYBNCybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry ProgramsBusiness Wire- Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline - - Osmind is a leading service provider to
1y agoCYBNCybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business HighlightsBusiness Wire- Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder ("MDD") - - PARADIGM
1y agoCYBNCybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderBusiness Wire- Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance - - First program member is
1y agoCYBNCybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025Business Wire- Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder ("MDD") - - Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating
1y agoCYBNCybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025Business WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy ResultsBusiness Wire- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough
1y agoCYBNCybin to Participate in Water Tower Research Fireside Chat on December 11, 2024Business WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
1y agoCYBNCybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive DisorderBusiness Wire- 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in
1y agoCYBNCybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024Business Wire- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc.
1y agoCYBNCybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial ResultsBusiness Wire- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH ™: A Phase III, Placebo-Controlled,
2y agoCYBNCybin to Participate at the 2024 Milken Institute Future of Health SummitBusiness Wire- CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough
2y agoCYBNCybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines ProgramBusiness Wire- The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders - - Cybin's sector-leading intellectual property portfolio now includes over 70 granted
2y agoCYBNCybin to Participate in Water Tower Research Fireside Chat on October 8, 2024Business WireCybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation
2y agoCYBNCybin Expands Clinical Team to Support CYB003 Phase 3 ProgramBusiness Wire- Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety &